美巴龙用于肾细胞癌的II期评估。

Phase II evaluation of merbarone in renal cell carcinoma.

作者信息

Flanigan R C, Saiers J H, Wolf M, Kraut E H, Smith A Y, Blumenstein B, Crawford E D

机构信息

Loyola University Medical Center, Maywood, Illinois.

出版信息

Invest New Drugs. 1994;12(2):147-9. doi: 10.1007/BF00874446.

DOI:10.1007/BF00874446

PMID:7860233

Abstract

The Southwest Oncology Group (SWOG) studied the response rate and toxicity of merbarone (1,000 mg/m2 IV continuous infusion days 1-5, q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 36 eligible patients, there was one partial response for a response rate of 3% (95% C.I. 0.1-15%). There were no mixed responses. There were no treatment related deaths or adverse drug reactions. Significant anemia, diarrhea, and hypercalcemia were observed. Mild to moderate degrees of malaise/fatigue/lethargy, dizziness/vertigo, hyperglycemia, creatinine increase, nausea, vomiting, weight loss, pedal edema, dyspnea, and granulocytopenia were noted. Merbarone does not have significant activity as a single agent in advanced renal cell carcinoma.

摘要

西南肿瘤协作组（SWOG）研究了美巴龙（1000mg/m²，静脉持续输注，第1 - 5天，每21天重复）对晚期转移性肾细胞癌患者的缓解率和毒性。在36例符合条件的患者中，有1例部分缓解，缓解率为3%（95%置信区间0.1 - 15%）。无混合反应。无治疗相关死亡或药物不良反应。观察到明显的贫血、腹泻和高钙血症。记录到轻至中度的不适/疲劳/嗜睡、头晕/眩晕、高血糖、肌酐升高、恶心、呕吐、体重减轻、足部水肿、呼吸困难和粒细胞减少。美巴龙作为单一药物在晚期肾细胞癌中没有显著活性。